Literature DB >> 1655202

Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model.

K Ikeda1, H Kumada, S Saitoh, Y Arase, K Chayama.   

Abstract

One hundred fifty-eight patients with hepatocellular carcinoma (HCC) were treated by transcatheter arterial embolization (TAE) as repeatedly as possible. Survival rates at the end of the first, second, and third year were 76.5%, 54.5%, and 41.1%, respectively. In 142 patients with repeated TAE, a significantly increased number of patients with complete necrosis of tumor was observed after repetition of the therapy. Adjusting the imbalance in prognostic factors among patients by using Cox proportional hazard model, it proved that the best response during the repeated therapy, rather than the first response, was significantly associated with survival period of the patients. Aside from the factor of response to the treatment, tumor size was the worst prognostic factor at the time when diagnosis was made. Other significant factors were portal vein invasion by HCC and bilirubin. The survival period of patients with HCC treated by repeated TAE was, therefore, affected by cancer factors, liver cirrhosis factors, and therapy-responsiveness factors. It is concluded that even if complete necrosis of tumor is not obtained after the first trial, repetition of TAE is an effective measure for prolonging of survival time in patients with HCC.

Entities:  

Mesh:

Year:  1991        PMID: 1655202     DOI: 10.1002/1097-0142(19911115)68:10<2150::aid-cncr2820681011>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?

Authors:  Koichiro Yamakado; Shiro Miyayama; Shozo Hirota; Kimiyoshi Mizunuma; Kenji Nakamura; Yoshitaka Inaba; Akihiro Maeda; Kunihiro Matsuo; Norifumi Nishida; Takeshi Aramaki; Hiroshi Anai; Shinichi Koura; Shigeo Oikawa; Ken Watanabe; Taku Yasumoto; Kinya Furuichi; Masato Yamaguchi
Journal:  Jpn J Radiol       Date:  2012-05-30       Impact factor: 2.374

2.  Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer--a pilot study.

Authors:  K Ikeda; S Saitoh; Y Suzuki; A Tsubota; I Koida; M Kobayashi; Y Arase; K Chayama; N Murashima; H Kumada
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

3.  Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients.

Authors:  Mikio Tezuka; Keiji Hayashi; Yoichi Okada; Tetsuya Irie; Hiroyasu Ina
Journal:  Dig Dis Sci       Date:  2008-07-23       Impact factor: 3.199

4.  Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.

Authors:  Masatoshi Kudo; Ryosuke Tateishi; Tatsuya Yamashita; Masafumi Ikeda; Junji Furuse; Kenji Ikeda; Norihiro Kokudo; Namiki Izumi; Osamu Matsui
Journal:  Clin Drug Investig       Date:  2012-08-08       Impact factor: 2.859

5.  Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization.

Authors:  F Farinati; N De Maria; C Marafin; L Herszènyi; S Del Prato; M Rinaldi; L Perini; R Cardin; R Naccarato
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 6.  Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review.

Authors:  Maria-Aggeliki Kalogeridi; Anna Zygogianni; George Kyrgias; John Kouvaris; Sofia Chatziioannou; Nikolaos Kelekis; Vassilis Kouloulias
Journal:  World J Hepatol       Date:  2015-01-27

7.  Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.

Authors:  Renumathy Dhanasekaran; David A Kooby; Charles A Staley; John S Kauh; Vinit Khanna; Hyun S Kim
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

8.  Chemotherapy v symptomatic treatment for hepatoma.

Authors:  F Farinati; N De Maria; C Marafin; L Herszenyi; R Naccarato; L Perini
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

9.  Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma and coexisting hepatic cavernous hemangioma.

Authors:  Ran-Chou Chen; Jiunn-Ming Lii; Wei-Tsung Chen; Hsing-Yang Tu; Liang-Chung Chiang
Journal:  Eur Radiol       Date:  2005-12-06       Impact factor: 5.315

10.  Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma.

Authors:  Marine Gross-Goupil; Raphaël Saffroy; Daniel Azoulay; Sophie Precetti; Jean-François Emile; Valérie Delvart; Fréderic Tindilière; Alexis Laurent; Marie-France Bellin; Henri Bismuth; Brigitte Debuire; Antoinette Lemoine
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.